Skip to main content
Ana Alarcon Tomas on Muck Rack

Ana Alarcon Tomas

As seen in: Nature, MDPI, Luxemburger Wort
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ana Alarcon

Contact Ana Alarcon, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Acceptability of remotely supervised Home-Based transcranial direct current stimulation combined with Cognitive-behavioural-based app for peripartum depression: perspectives from women with lived experience and mental health professionals | Scientific Rep

|
By Ana Ganho-Ávila, Andreia Cruz, Nina Szczygiel, Ana Alarcon Tomas, Ana María Tomás, Catarina M Azevedo, Pedro Pestana Bastos, Mariana Moura-Ramos
| Nature Verified
Abstract Peripartum depression (PPD) has a global prevalence of 20% significantly impacting societies. Yet, existing treatments face barriers for its uptake. This study examined the acceptability of a remotely supervised home-based transcranial direct current stimulation (tDCS) solution combined with a CBT-based app (the FLOW Neuroscience solution) for PPD, among women (experts by experience; EEs) and healthcare professionals (HPs).
Open in Who Shared Issue with article?

An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma - Nature Medicine

|
By Sandeep Raj, Shalev Fried, Andrew Ip, Joshua A. Fein, Ana Alarcon Tomas, Jonathan Peled, Tyler Funnell, Elad Jacoby, Richard J. Lin, Jae Park, M. Lia Palomba, Gilles Salles, Amethyst Saldia, Inbal Sdayoor, Benjamin D. Greenbaum, Andrew J. Vickers, Hyung C. Suh, Miguel-Angel Perales
| Nature Verified
Abstract Disease progression is a substantial challenge in patients with non-Hodgkin lymphoma (NHL) undergoing chimeric antigen receptor T cell (CAR-T) therapy. Here we present InflaMix (INFLAmmation MIXture Model), an unsupervised quantitative model integrating 14 pre-CAR-T infusion laboratory and cytokine measures capturing inflammation and end-organ function.
Open in Who Shared Issue with article?

Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT |

|
By Ana Alarcon Tomas, Edouard Forcade, Vladan Vucinic, Nicolaus Kröger, Lucía López Corral, Jan Vydra, Bastian von Tresckow, Marie Therèse Rubio, Rafael Hernani, Simona Sica, Friedrich Stölzel, Eva Wagner-Drouet, José Antonio Pérez-Simón, Isabel Ortega, Florent Malard, Jürgen Kuball
| Nature Verified
Chimeric antigen receptor (CAR) T-cells have ushered in a new era of adoptive cell immunotherapies and caused a paradigm shift in the treatment of relapsed and refractory B-cell lymphomas [1].
Open in Who Shared Issue with article?
See all 7 licensed articles (9 Total)